Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2.
To develop a herpes virus vaccine that can induce immunity for an extended period, a recombinant Marek's disease (MD) virus (MDV) CVI-988 strain expressing infectious bursal disease virus (IBDV) host-protective antigen VP2 at the US2 site (rMDV) was developed under the control of an SV40 early promoter. Chickens vaccinated with the rMDV showed no clinical signs and no mortality and 55% of the chickens were considered protected histopathologically after challenge with very virulent IBDV (vvIBDV), whereas all of the chickens vaccinated with the conventional IBDV vaccine showed no clinical signs and were protected. Chickens vaccinated with the CVI-988 or chickens in the challenge control showed severe clinical signs and high mortality (70-75%) and none of them were protected. Also, the rMDV conferred full protection to chickens against vvMDV just as the CVI-988 strain did, whereas 90% of the challenge control chickens died of MD. Antibody levels against IBDV and MDV following the vaccination increased continuously for at least 10 weeks. No histopathological lesions in the rMDV-vaccinated chickens and no contact transmission of the rMDV to their penmates were confirmed. These results demonstrate that an effective and safe recombinant herpesvirus-based IBD vaccine could be constructed by expressing the VP2 antigen at the US2 site of the CVI-988 vaccine strain.
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D018175:Birnaviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D002642:Chick Embryo; D002645:Chickens; D003257:Consumer Product Safety; D004195:Disease Models, Animal; D005822:Genetic Vectors; D008381:Herpesvirus 2, Gallid / Q000276:immunology*; D007243:Infectious bursal disease virus / Q000276:immunology* / Q000472:pathogenicity; D008380:Marek Disease / Q000517:prevention & control*; D011817:Rabbits; D011995:Recombination, Genetic; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*; D015678:Viral Structural Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*; D014774:Virulence